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Background: Adoptive therapy with tumour-infiltrating lymphocytes (TILs) induces durable complete responses (CR) in B20% of
patients with metastatic melanoma. The recruitment of T cells through CXCR3/CCR5 chemokine ligands is critical for immune-
mediated rejection. We postulated that polymorphisms and/or expression of CXCR3/CCR5 in TILs and the expression of
their ligands in tumour influence the migration of TILs to tumours and tumour regression.
Methods: Tumour-infiltrating lymphocytes from 142 metastatic melanoma patients enrolled in adoptive therapy trials were
genotyped for CXCR3 rs2280964 and CCR5-D32 deletion, which encodes a protein not expressed on the cell surface.
Expression of CXCR3/CCR5 in TILs and CXCR3/CCR5 and ligand genes in 113 available parental tumours was also assessed.
Tumour-infiltrating lymphocyte data were validated by flow cytometry (N¼ 50).
Results: The full gene expression/polymorphism model, which includes CXCR3 and CCR5 expression data, CCR5-D32
polymorphism data and their interaction, was significantly associated with both CR and overall response (OR; P¼ 0.0009,
and P¼ 0.007, respectively). More in detail, the predicted underexpression of both CXCR3 and CCR5 according to gene
expression and polymorphism data (protein prediction model, PPM) was associated with response to therapy (odds ratio¼ 6.16
and 2.32, for CR and OR, respectively). Flow cytometric analysis confirmed the PPM. Coordinate upregulation of CXCL9, CXCL10,
CXCL11, and CCL5 in pretreatment tumour biopsies was associated with OR.
Conclusion: Coordinate overexpression of CXCL9, CXCL10, CXCL11, and CCL5 in pretreatment tumours was associated with
responsiveness to treatment. Conversely, CCR5-D32 polymorphism and CXCR3/CCR5 underexpression influence downregulation
of the corresponding receptors in TILs and were associated with likelihood and degree of response.
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Adoptive therapy with autologous tumour-infiltrating T lymphocytes
(TILs) represents a promising treatment for patients with
metastatic melanoma. In phase II trials, where TILs are expanded,
activated ex vivo, and then adoptively transferred into patients in
combination with systemic high-dose interleukin-(IL)-2 following
lymphodepletion, durable complete responses (CR) were observed
in B20% of patients (Rosenberg et al, 2011). However, the
administration of preparative chemotherapy and high-dose IL-2 is
associated with significant toxicity and no pretreatment biomar-
kers of responsiveness useful for patient selection are currently
available.
Several studies in humans and animal models suggest that the
recruitment of activated T lymphocytes through CXCR3 and CCR5
chemokine ligands has a key role immune-mediated tissue
destruction, including tumour rejection (Wang et al, 2008;
Bedognetti et al, 2010; Gajewski et al, 2011; Spivey et al, 2011;
Gonzalez-Martin et al, 2012). We observed that systemically
administered IL-2 induces inflammation within tumours leading to
production of lymphocyte chemoattractants including CXCR3 and
CCR5 ligands (Panelli et al, 2002; Panelli et al, 2004a; Bedognetti
et al, 2010; Weiss et al, 2011). Indeed, the localisation of TILs
within tumours is a necessary, although not sufficient, condition
for tumour rejection (Pockaj et al, 1994). Thus, we postulated that
polymorphisms and/or expression of CXCR3 and CCR5 may
quantitatively and/or qualitatively influence chemokine receptor
expression, and therefore influence migration of TILs to tumours
and their regression.
The CCR5 polymorphism D32 consists of a 32-base deletion
encoding a protein not expressed on the cell surface. Consequently,
heterozygosity results in decreased and homozygosity absent
receptor expression (Huang et al, 1996; Carrington et al, 1999).
A retrospective study reported decreased survival of patients with
metastatic melanoma carrying the CCR5-D32 polymorphism
treated with immunotherapy (Ugurel et al, 2008). A common
single nucleotide polymorphism (rs2280964) of CXCR3 has been
recently associated with variation in receptor expression,
lymphocyte chemotactic activity, and risk of developing asthma
(Choi et al, 2008).
Here, in a prospective-retrospective hypothesis-driven analysis
(Simon et al, 2009), we investigated the role of CXCR3 and CCR5
expression and polymorphisms (i.e., rs2280964 for CXCR3 and
D32 for CCR5) by sequencing and profiling infused TILs from
patients with metastatic melanoma undergoing adoptive therapy
(N¼ 142). Results were validated using flow cytometry (N¼ 50).
The role of CXCR3/CCR5 ligand gene expression was assessed
by profiling matched pretreatment tumour biopsies (N¼ 113).
MATERIALS AND METHODS
Patient samples. Samples from 142 patients were available:
142 TILs and 113 paired pretreatment tumour biopsies for RNA
extraction, and 141 TILs for DNA extraction. Fifty paired
TIL samples were also analysed using flow cytometry. Tumour-
infiltrating lymphocytes were frozen just before the infusion.
Samples were collected during five consecutive trials at the Surgery
Branch, National Cancer Institute (Dudley et al, 2010; Rosenberg
et al, 2011; Uccellini et al, 2012; http://www.clinicaltrials.gov/
ct2/show/NCT00513604?term=07C0176&rank=1), codified as:
TNMA, T200, T1200, TYT, and TCD8 (Table 1). All patients
had progressive disease and had previously received standard or
experimental regimens. Fifty percent of the patients (71 out of 142)
achieved an objective response (OR), of which 25 (18%)
experienced a durable CR and 46 (32%) a partial response (PR).
Tumour biopsy samples included 24 CR (21%), 34 PR (30%) and
55 (49%) non-response (NR) samples.
Total body irradiation (TBI; 2 or 12Gy) was administered in
conjunction with chemotherapy in T200 and T1200 trials,
respectively (Rosenberg et al, 2011). A day following lymphodeple-
tion, TILs were infused into patients and high-dose IL-2 therapy
was started. Protocols employed to generate TILs are described
elsewhere (Dudley et al, 2003; Tran et al, 2008; Dudley et al,
Table 1. Patient and treatment characteristics
CR NR NR
All, n¼142
n (%) Objective response (OR vsNR)*
Complete response
(CR vs non-CR)*
Sex
Female vs male
Odds ratio (95% CI)
Female vs male
Odds ratio (95% CI)
Male n (%) 15 (17) 29 (33) 45 (51) 89 (63) 1.06 (0.54–2.10) 1.15 (0.47–2.78)
Female n (%) 10 (19) 17 (32) 26 (49) 53 (37) P-value P-value
0.86 0.76
Age (median: 46; range: 18–64)
Age
P-value
Age
P-value
16–30 n (%) 3 (20) 3 (20) 9 (60) 15 (11) 0.43 0.50
31–45 n (%) 9 (18) 17 (33) 25 (49) 51 (36)
46–60 n (%) 13 (20) 23 (35) 30 (46) 66 (47)
61–75 n (%) 0 (0) 3 (30) 7 (70) 10 (7)
Treatment
Treatment
P-value
Treatment
P-value
TNMA n (%) 5 (13) 13 (33) 21 (54) 39 (28) 0.015 0.017
T200 n (%) 5 (21) 8 (33) 11 (46) 24 (17)
T1200 n (%) 10 (40) 8 (32) 7 (28) 25 (18)
TYT n (%) 2 (8) 4 (16) 19 (76) 25 (18)
TCD8 n (%) 3 (10) 13 (45) 13 (45) 29 (20)
Abbreviations: CI¼ confidence interval; CR¼ complete response; NR¼ no response; Non-CR¼PRþNR; OR¼objective response (CRþPR); PR¼partial response; T200¼ 2Gy total body
irradiation protocol; T1200¼ 12Gy total body irradiation protocol; TCD8¼ young TIL CD8-enriched protocol; TNMA¼ no total body irradiation protocol; TYT¼ young TIL protocol. *P-values
are from the w2-test or the Fisher’s exact test, as appropriate.
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2010; Rosenberg et al, 2011). Before TIL administration, patients
received a non-myeloablative lymphodepleting regimen consisting
of cyclophosphamide at 60mg kg 1 per day for 2 days and
fludarabine at 25mgm 2 per day for 5 days (Dudley et al, 2010;
Rosenberg et al, 2011). A day following lymphodepletion,
TILs were infused into patients and high-dose IL-2 therapy was
started (720 000 IU kg 1 intravenously every 8 h to tolerance).
Major inclusion criteria included minimum age of 18 years,
measurable disease, good clinical performance and life expectancy
greater than 3 months. Detailed study protocol information
are available elsewhere (http://www.clinicaltrials.gov/ct2/show/
NCT00513604?term=07C0176&rank=1), (Dudley et al, 2010;
Rosenberg et al, 2011).
All patients signed an informed consent approved by the
Institutional Review Board of the National Cancer Institute.
Data for this analysis are updated as of 11 January 2012. Response
(CR, PR, or NR) was rated according to the Response Evaluation
Criteria in Solid Tumors guidelines 4 weeks following TIL
administration and at regular intervals thereafter. A CR or PR was
considered an OR and a PR or NR was considered a non-CR.
Sequencing. DNA was successfully extracted from 141 TIL
samples from frozen material (cell pellet) preserved at  80 1C.
One sample was unavailable for DNA extraction. Total DNA was
isolated with the Nucleic Acid Isolation System QuickGene-810
using the QuickGene DNA whole blood Mini Kit (Fujifilm, Tokyo,
Japan).
Amplification PCR was carried out in a reaction mixture
containing 4ml (40 ng) of DNA, 10 ml of HotStar Taq Master Mix
(Qiagen, Germantown, MD, USA), 1 ml (10 pmol) of each of the
following primers: forward 50-CTGGCCATCTCTGACCTGTT-30
and reverse 50-CCCTGTGCCTCTTCTTCTCA-30 for CCR5 gene
(D32 polymorphism) and forward 50-CTCCCTACACTGAGG
CTTGC-30 and reverse 50-AGCCATGGTCCTTGAGGTAA-30 for
CXCR3 gene (rs2280964 polymorphisms). Primers were designed
using the Primer3 software (http://www.frodo.wi.mit.edu/).
For CCR5 analysis, the reaction mixture was denatured at 95 1C
for 10min and cycled 35 times at 94 1C for 30 s, 58 1C for 30 s, and
72 1C for 60 s, with final extension at 72 1C for 10min. For CXCR3
analysis, the reaction mixture was denatured at 95 1C for 10min
and cycled 32 times at 94 1C for 45 s, 58 1C for 45 s, and 72 1C for
60 s, with the final extension at 72 1C for 10min.
The PCR product was purified with Exosap-IT (USB Corpora-
tion, Cleveland, OH, USA) according to the manufacturer’s
protocol. PCR products were visualised on ultraviolet transillumi-
nated, ethidium bromide 2% Agarose gel (Invitrogen, Carlsbad,
CA, USA).
Sequencing reactions were performed using 3.5 ml of purified
DNA product, 2 ml of Big Dye terminator (Big Dye Terminator
v3.1 cycle sequencing reaction kit, Applied Biosystems, Foster City,
CA, USA) and 4 pmol of forward primer. The following conditions
were used: initial temperature of 96 1C for 60 s, followed by 30
cycles at 96 1C for 30 s, 50 1C for 30 s, and 60 1C for 4min. Excess
dye terminators were removed using DyeEx 96 Kit columns as per
the manufacturer’s instructions (Qiagen).
The Sanger sequencing was performed on an ABI Prism 3730
XL instrument (Applied Biosystems). Data were analysed using
Sequencher software v.4.9 (Gene Codes Corporation, Ann Arbor,
MI, USA).
Samples for gene expression and sequencing experiments were
processed in parallel during the same time period.
Gene expression. Total RNA was isolated from 142 TILs
(cryopreserved just before the infusion into the patients) and 113
snap frozen tumour samples used for TIL generation. Total RNA
was extracted with the Qiagen miRNeasy Mini kit and its quality
was tested with the Agilent Bioanalyzer 2000 (Agilent Techno-
logies, Palo Alto, CA, USA). Three hundred nanograms of total
RNA were used for RNA amplification according to the manu-
facturer’s instructions (WT Expression Kit; Ambion, Austin, TX,
USA). Amplified RNA was reverse transcribed into cDNAs followed
by fragmentation. After hybridisation to the GeneChip Human
Gene 1.0 ST Arrays, the chips were labelled with a WT Terminal
Labeling Kit (Affymetrix, Santa Clara, CA, USA) and scanned on a
GeneChip Scanner 3000 7G (Affymetrix). Data were normalised
using the Robust Multi-Chip Average method and Log2-transformed
using Partek Genomics Suite 6.4 (Partek Inc., St Louis, MO, USA).
Data analyses were based on the whole transcripts.
Flow cytometry. Flow cytometry was performed in 50 TIL
samples (cryopreserved just before the infusion into the patients)
to validate the accuracy of genomic data in predicting cell surface
protein expression. Tumour-infiltrating lymphocytes were selected
as follows: (a) all available CRs; (2) samples concomitantly under-
or overexpressing CXCR3 and CCR5; (3) CCR5-D32 homozygous
samples; and (4) CCR5-D32 heterozygous samples included in the
protein prediction model (PPM; described in the Results section).
Because of the non-random sampling (selection bias), a correlation
analysis between receptor expression and response was neither
planned nor performed. Tumour-infiltrating lymphocyte samples
included 18 CR (11 CXCR3/CCR5 low and 7 CXCR3/CCR5 high),
3 PR (CXCR3/CCR5 high) and 29 NR (14 CXCR3/CCR5 low and
15 CXCR3/CCR5 high) cases. Ten CCR5-D32 heterozygous (six PR,
two CR and two NR) and one CCR5-D32 homozygous samples
were selected, including six samples that were reclassified as the
low group according to the PPM. Tumour-infiltrating lymphocytes
preserved in liquid nitrogen were thawed, washed, immediately
stained and analysed. FITC-labelled anti-CCR5 and PE-labelled
anti-CXCR3 antibodies were used for chemokine receptor expres-
sion analyses. 7AAD antibodies were used to identify dead cells
allowing for gating and analysis of live cells only. Samples were also
stained with the appropriate isotype controls. Cells were analysed
on a FACSCalibur flow cytometer (Becton Dickinson & Co, San
Jose, CA, USA). Thirty thousand events were acquired on the
FACSCalibur from each of the TIL samples for analysis. Daily
fluctuations of the FACSCalibur flow cytometer were controlled by
using Sphero 8 peak Rainbow Calibration Particles (Becton
Dickinson & Co) and specific fluorescencent signal were calculated
on the live cells by normalising to the appropriate isotype control,
as described elsewhere (Pos et al, 2010). All of the antibodies were
from Becton Dickinson & Co. Samples were stained according to
the manufacturer’s protocols.
Statistical analysis. The difference of the overall outcome
distribution (CR, PR, and NR) among CXCR3 and CCR5
polymorphism classes was assessed using the Kruskal–Wallis test
that accounts for the ordered nature of the outcomes (i.e., degree of
response: CR better than PR better than NR). The distribution of
OR and CR between CXCR3 and CCR5 classes was then assessed
by the w2-test or Fisher’s exact test, as appropriate (i.e., if any
category has a cell counto5). Odds ratios with their 95% CI were
also reported, as appropriate. To minimise ‘data overfitting biases’,
statistical significance levels and confidence intervals are not
reported for data-derived hypotheses. As for the CXCR3 rs2280964
polymorphism, the four G carriers were not included in the
genotype-response and genotype-transcript level correlation
analysis. The associations between the expression of CXCR3 and
CCR5 in TILs and clinical responses were first assessed individually
by the Spearman rank correlation coefficient (r) tests, which
account for the ordered nature of the outcomes. One sample was
unavailable for genotyping. Logistic regression models were used to
assess the joint association between the expression of CXCR3 and
CCR5, the CCR5-D32 polymorphism, and their interactions with
the clinical outcome, defined as either CR or OR. The log
likelihood ratio test to was used to compare the fit of two models,
one of which (the null model) is a special case of the other
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(the alternative model). The test is based on the log likelihood ratio,
which expresses how many times more likely the data are under one
model than the other. The null distribution of log likelihood is
generated by calculating the log likelihood for each permutation.
The variables included in the model are defined as follows: X1, X2,
X3 are binary variables; X1¼ 1 when Log2 gene expression value
of CCR54median; X1¼ 0 when Log2 gene expression value of
CCR5pmedian; X2¼ 1 when Log2 base gene expression value
of CXCR34median; X2¼ 0 when Log2 base gene expression value
of CXCR3pmedian; X3¼ 0 when CCR5 polymorphism D32 is
present; wild-type (WT)¼ 1; Rx¼ treatment (TNMA, T200,
T1200, TYT, and TCD8); Y: end point (CR or OR). During the
model fitting, the sample with missing genotype data was omitted.
The gene expression model included CXCR3 and CCR5
expression and their interaction (model A). The gene expression/
polymorphism model included CXCR3 and CCR5 expression,
CCR5-D32 polymorphism, and their interaction (model B).
Likelihood ratio tests were used to evaluate the statistical
significance of effects in the models compared. The gene
expression and the gene expression/polymorphism models were
also controlled for treatment effect by including treatment
variables in the two models (model C and model D, respectively).
In order to facilitate interpretation of the statistically significant
interactions found in the logistic regression models, CXCR3 and
CCR5 expression data were then dichotomised (low vs high)
according to their respective median values and integrated with each
other and with CCR5-D32 polymorphism data, resulting in a PPM.
Univariate associations between TIL and tumour CXCR3 and
CCR5 expression and their polymorphisms were assessed by
Student’s t-test (CCR5-D32 polymorphism) after checking for
normal distribution (the D0Agostino–Pearson normality test) or by
the Spearman rank correlation coefficient (r) test (CXCR3
rs2280964 polymorphism). Association between sex, age and
clinical outcomes (CR or OR), as well as cluster enrichment
analysis was assessed by the w2- or Fisher exact test, as appropriate.
Correlation between flow cytometry and gene expression data
was assessed by the Spearman rank correlation coefficient (r) test
as flow cytometry data were not normally distributed.
The correlation matrix of tumour biopsy gene expression data
was based on the Spearman rank correlation coefficient (r) test
because not all the data were normally distributed. Hierarchical
clustering was based on the Euclidean distances, and was
performed with Partek Genomics Suite 6.4. Probability (P) values
o0.05 (two-sided) were considered to be statistically significant.
All statistical tests were two sided. Analyses were performed with
SPSS version 18.0 (SPSS, Chicago, IL, USA), Partek Genomics Suite
6.4 (Partek Inc., and R (Bedognetti et al, 2011).
Single subject CXCR3 rs2280964 genotypes (HapMap and 1000
Genome Projects, CEU populations) were downloaded from
ensembl (http://www.useast.ensembl.org/index.html).
RESULTS
Tumour-infiltrating lymphocyte sequencing. Demographic
characteristics of the study population are shown in Table 1. As
for CXCR3 (located on the X chromosome), no association was
observed between response and rs2280964 genotype (Table 2). The
frequencies of T allele were 0.24 and 0.30 in men and women,
respectively. These frequencies are similar to those reported in
individuals with European ancestry (T-allele frequency in men:
0.26 and 0.20, CEU HapMap, and CEU 1000 Genomes Project,
respectively; T-allele frequency in women: 0.22 and 0.27, CEU
HapMap, and CEU 1000 Genomes Project, respectively). Interest-
ingly, we found four men (one CR, two PR, and one NR) carrying
the G allele (electopherograms in Supplementary Figure S1).
Although rs2280964 is annotated as bi-allelic (C/T) polymorphism
in the dbSNP database (http://www.ncbi.nlm.nih.gov/snp/
?term=2280964), HapMap project and genome-wide association
studies (both array based) might miss the identification of tri-allelic
variants (Ellinghaus et al, 2009). In fact, array-based genotyping
need the knowledge of a third allele being present for the assays
design, otherwise the third allele cannot be detected without using
appropriate imputation algorithms (Huebner et al, 2007). However,
programs used to genotype the current phase 1 release of 1000
Genomes Projects (sequencing based) are unable to genotype sites
with more than two alleles. (http://www.1000genomes.org/faq/
are-all-genotype-calls-current-release-vcf-files-bi-allelic).
As for CCR5, the frequency of the D32 genotype is B20% in
Caucasians (Carrington et al, 1999). Similarly, we found 26
patients (18.4%) carrying the D32 polymorphism (1 homozygous
and 25 heterozygous). The difference in the overall distribution of
the outcomes for the WT and D32 patients was borderline
significant (P¼ 0.058) when checked with the Kruskal–Wallis test
that assumes a progressive enrichment of one genotype over the
other in three ordered response classes (i.e., CR4PR4NR).
Although the CR rate was similar between the two groups (24% vs
16%), 17 of 25 patients (68%) carrying the D32 polymorphism
(including the homozygous patients) experienced an OR, whereas
only 53 of 116 (46%) WT patients experienced an OR (odds
ratio¼ 2.53, CI¼ 1.01–6.32, D32 vs WT patients, respectively,
P¼ 0.043, Table 2).
Tumour-infiltrating lymphocyte gene expression and integrated
gene expression and sequencing analysis. No differences in
CXCR3 and CCR5 expression in TILs among the response classes
was observed when data were compared by the Spearman rank
correlation coefficient (r) test, which assumes a progressive
change in gene expression in the three ordered response classes
(i.e., CR4PR4NR or CRoPRoNR), having CR and PR samples
the lowest and the highest transcript levels (CXCR3 and CCR5 gene
expression data distribution is shown in Supplementary Figure S2).
To evaluate the weight on response of the coordinate expression
of CXCR3 and CCR5, which have redundant functions, we utilised
logistic regression analyses (Table 3). The gene expression model
with interaction (full A model), included as predictor variables the
expression of the two genes in TILs and the two-way interaction
between the individual gene expressions. This model was
significantly associated with CR (P¼ 0.032) but not significantly
associated with OR (P¼ 0.15). The gene expression/polymorphism
model with interaction (full B model) includes the variables of the
full A model as well as an indicator variable for D32 polymorphism
and the two-way and three way interaction of the CCR5-D32
polymorphism with the gene expression variables. By adding the
DNA dimension (CCR5-D32 polymorphism), the model was
significantly associated with both CR (P¼ 0.0009) and OR
(P¼ 0.007). The gene expression/polymorphism model with
interaction (full B model) performed significantly better than the
gene expression model with interaction (full A model) for both CR
(P¼ 0.003) and OR (P¼ 0.007). As we detected a significant
difference in OR and CR rates across the cohorts (see demographic
characteristics in Table 1), we also evaluated models containing a
treatment group factor, as well as the other variables. With this
adjustment (model C and D), the gene expression model with
interaction (full C model) remained significantly associated with
CR (P¼ 0.002), and became also significantly associated with OR
(P¼ 0.010). The gene expression/polymorphism model with
interaction (full D model) remained significantly associated with
CR (P¼ 0.0001) and with OR (P¼ 0.003) and, again, was
significantly better than the gene expression model with interaction
for CR and OR (P¼ 0.005 and P¼ 0.036, respectively). A detailed
description of the results of the logistic regression models,
including intermediate models, is reported in Supplementary
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Tables S1 and S2. Despite the possible intrinsic data overfitting, the
employment of logistic models, which assess all the combination
among the variables analysed, reduce biases related to the selection
of group comparisons. Overall, these models clearly (and
consistently) show that the addition of new dimensions to data
(e.g., combinatorial gene expression analysis and integration with
genetic polymorphisms) can increase the chances to identify
patients more probably to respond to treatment.
To understand the significant interactions identified by the
logistic modelling, samples were grouped according to the
expression of chemokine receptor genes. The CXCR3-low
group was enriched in CR samples (CR rate: 25% vs 10%,
odds ratio¼ 3.11, CXCR3 low vs high, respectively, Figure 1A).
The CCR5-low group was also slightly enriched in CR samples
(CR rate: 21% vs 14%, odds ratio¼ 1.63, CCR5 low vs high,
respectively). Similar OR rate was observed in CXCR3-low group
(as compared with CXCR3 high group), and in CCR5-low group
(as compared with CCR5-high group, Figure 1B).
We then explored the coordinate underexpression of both
transcripts. The samples with CXCR3 and CCR5 expression values
below the median were grouped in the category CXCR3/CCR5 low
(n¼ 41) and those with at least one above the median were
grouped as CXCR3/CCR5 high (n¼ 101). Co-underexpression of
both genes was strongly associated with achievement of CR: 32% of
patients in the CXCR3/CCR5-low group achieved a CR compared
with 12% in the CXCR3/CCR5-high group (odds ratio¼ 3.44,
Figure 1A). A similar trend was observed in the OR analysis
(Figure 1B).
As the protein expression of CCR5 on TIL cell surface was
expected to be reduced in CCR5-D32 patients (partially in
heterozygous, complete in homozygous), we integrated this
variable (i.e., CCR5-D32 polymorphism) with gene expression
values to build a PPM. In the PPM (rational explained in detail in
Figure 2), CCR5-D32 carriers with high CCR5 transcript levels
(CCR5 high) were included in the CCR5-low (PPM) group and in
the CXCR3/CCR5-low (PPM) group if CXCR3 was low. By adding
Table 2. Correlation between CXCR3 and CCR5 polymorphisms and outcome
CXCR3
rs2280964 CR PR NR
All, n¼141
n (%)
Responsea
(CR4PR4NR)
Objective responseb
(OR vs NR)
Complete responseb
(CR vs non-CR)
C (CC or C/-) C/T vs TþC
C/T vs TþC
Odds ratio (95% CI)
C/T vs TþC
Odds ratio (95% CI)
All n (%) 15 (17) 26 (30) 46 (53) 87 (62) All¼1.28 (0.54–3.01) All¼ 0.83 (0.26–2.67)
Male n (%) 9 (14) 21 (33) 33 (52) 63 (45) Female¼ 1.26 (0.43–3.70) Female¼ 0.64 (0.16–2.58)
Female n (%) 6 (25) 5 (21) 13 (54) 24 (17)
P-value P-value P-value
All¼ 0.75 All¼0.58 All¼0.75
Female¼ 0.94 Female¼0.68 Female¼0.52
CT Cþ C/T vs T
Cþ C/T vs T
Odds ratio (95% CI)
CþC/T vs T
Odds ratio (95% CI)
All (female) n (%) 4 (15) 10 (39) 12 (46) 26 (18) All¼0.95 (0.39–2.29) All¼ 0.77 (0.26–2.31)
Male¼1.00 (0.37–2.27) Male¼0.53 (0.16–1.82)
Female¼ 0.50 (0.04–5.87) Female¼ 1.81 (0.08–37.93)
T (TT or T/-) P-value P-value P-value
All n (%) 5 (21) 7 (29) 12 (50) 24 (17) All¼ 0.80 All¼0.91 All¼0.77
Male¼0.73 Male¼1.00 Male¼ 0.32
Female¼ 0.92 Female¼1.00 Female¼1.00
Male n (%) 5 (24) 5 (24) 11 (52) 21 (15) C vs TþT/C C vs TþT/C
Female n (%) 0 (0) 2 (67) 1 (33) 3 (2) C vs Tþ T/C Odds ratio (95% CI) Odds ratio (95% CI)
All¼0.82 (0.41–1.65) All¼ 0.95 (0.38–2.36)
Male¼1.00 (0.37–2.69) Male¼0.53 (0.16–1.82)
Female¼ 0.69 (0.23–2.04) Female¼ 2.08 (0.51–8.47)
P-value P-value P-value
All¼ 0.64 All¼0.59 All¼1.00
Male¼0.73 Male¼1.00 Male¼ 0.32
Female¼ 0.90 Female¼0.49 Female¼0.48
CCR5-D32 CR PR NR
All, n¼141
n (%)
Response
(CR4PR4NR)
Objective response
(OR vs NR)
Complete response
(CR vs non-CR)
D32
D32 vs WT
Odds ratio (95% CI)
D32 vs WT
Odds ratio (95% CI)
All n (%) 6 (24) 11c (44) 8 (32) 25 (18) 2.53 (1.01–6.32) 1.61 (0.57–4.57)
WT P-value P-value P-value
All n (%) 19 (16) 34 (29) 63 (54) 116 (82) 0.058 0.043 0.37
Abbreviations: CI¼ confidence interval; CR¼ complete response; Non-CR¼PRþNR; NR¼ no response; OR¼objective response (CRþPR); PR¼partial response; WT¼wild-type. One sample
(PR) was not available for genotyping. As the CXCR3 gene is located on the X chromosome, the association between CXCR3 rs2280964 genotype and response was also separately evaluated in
men and women. The four (men) patients carrying rs2280964 G allele ( one CR, two PR, one NR) were not included in the correlative analysis.
aP-values are from the Kruskall–Wallis test.
bP-values are from the w2-test or Fisher’s exact test, as appropriate.
cIncluded one patient homozygous for D32 polymorphism.
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this dimension, the disproportion of CR and OR samples between
the CXCR3/CCR5-low vs -high group (PPM) increased (CR rate:
36% vs 8%, odds ratio¼ 6.16; OR rate 64% vs 43%, odds
ratio¼ 2.32, CXCR3/CCR5 low vs high (PPM), respectively).
No association was observed between expression of CXCR3 or
CCR5 and the corresponding polymorphism in TILs or in tumour
samples (Supplementary Figure S3).
Tumour-infiltrating lymphocyte flow cytometry. We validated
the correlation between transcript and protein level in 50 available
TIL samples (Figure 3). All TIL samples displayed strong,
although variable, expression of CXCR3. CCR5 expression was
weaker. The fluorescence intensity curve of the two chemokine
receptors assumed a skewed Gaussian distribution without the
evidence of well-defined subpopulations. Protein expression of
CXCR3 correlated with the expression of their respective
transcripts (Figure 3A). CCR5 transcript expression and CCR5
protein expression correlated in both WT and D32 samples
(Figure 3E and F). CCR5-D32 strongly influenced the expression
of CCR5 protein. The lower expression of CCR5 protein in
CCR5-D32 in monocytes and T cells from CCR5-D32 carriers has
been previously demonstrated (Carrington et al, 1999), but no
data are available (to the best of our knowledge) on TILs. In fact,
TILs used for adoptive therapy are cultured and expanded
in vitro with consequent possible modulation of surface markers.
We observed that the level of CCR5 receptor in CCR5-D32
heterozygous samples expressing high levels of CCR5 transcripts
was approximately the half of that detected in CCR5 WT samples
(Figure 3D). No expression of CCR5 receptor on cell surface was
observed (as expected) in the CCR5-D32 homozygous sample.
Therefore, even if post-transcriptional changes could influence
the expression of CCR5 receptor (Shimizu et al, 2009), the
presence of D32 polymorphism has a major role in lowering the
expression of CCR5 protein in presence of high CCR5 transcripts
in TILs.
Despite the bias selection (see Materials and Methods section), it
is noteworthy that only 1 out of 18 CR samples overexpressed both
chemokine receptors (Figure 4). Thus, flow cytometry confirmed
the PPM suggesting that estimates based on germ line and
transcriptional data could be extended to the remaining samples
for which TILs were no longer available.
Pretreatment tumour biopsy gene expression. We investigated
the role of the coordinate intratumoral expression of CXCR3/
CXCR3 ligand gene expression (i.e., CXCL9, CXCL10, and
CXCL11) and CCR5/CCR5 ligands (i.e., CCL3, CCL4, and CCL5)
in 113 available pretreatment tumour biopsies used for TIL
generation.
CXCL9, CXCL10, CXCL11 and CCL5 were co-expressed
(Figure 5A) and, when used for hierarchical clustering analysis
Table 3. Association between TIL CXCR3, CCR5 expression, CCR5-D32 polymorphism, and their interaction, with clinical outcome
Model A (gene expression model): expression of CXCR3 and CCR5, and their interactions
Full model definition Association with clinical outcome
Comparator
Outcome
P-valuea
Full model A CR OR
YBuþ x1þ x2þ x1x2 YBu 0.032 0.15
Model B (gene expression/polymorphism model): expression of CXCR3 and CCR5, and CCR5-D32 polymorphism
Full model definition Association with clinical outcome
Comparator
Outcome
P-valuea
Full model B CR OR
YBuþ x1þ x2þ x3þ x1x2þ x1x3þ x2x3þ x1x2x3 YBu 0.0009 0.007
Full model A 0.003 0.007
Model C (gene expression and treatment model): treatment, expression of CCR5and CXCR3, and their interactions
Full model definition Association with clinical outcome
Comparator
Outcome
P-valuea
Full model C CR OR
YBuþRxþ x1þ x2þ x1x2 YBuþRx 0.002 0.010
Model D (gene expression/polymorphism and treatment model): treatment, expression of CXCR3 and CCR5, CCR5-D32 polymorphism,
and their interactions
Full model definition Association with clinical outcome
Comparator
Outcome
P-valuea
Full model D CR OR
YBuþRxþ x1þ x2þ x3þ x1x2þ x1x3þ x2x3þ x1x2x3 YBuþRx 0.0001 0.003
Full Model C 0.005 0.036
Abbreviations: CR¼ complete response; OR¼overall response; Rx¼ treatment (TNMA, T200, T1200, TYT, and TCD8); TIL¼ tumour-infiltrating lymphocyte; Y¼ end point (CR or OR);
YBu¼ null model; X1¼ expression of CCR5; X2¼expression of CXCR3; X3¼CCR5-D32 polymorphism.
aThe log likelihood ratio test to was used to compare the fit of two models, one of which (the null model) is a special case of the other (the alternative model). The test is based on the log
likelihood ratio, which expresses how many times more likely the data are under one model than the other. During the model fitting, the sample with missing genotype data was omitted.
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based on mean-centered expression values (Figure 5B), segregated
melanoma metastases into three main groups: cluster 1 included
samples with low CXCR3 and CCR5 ligand gene expression;
cluster 2 and cluster 3 with intermediate and high expression,
respectively. Cluster 1 was disproportionately enriched with
samples from NR patients (OR rate: 38%, P¼ 0.030) and cluster
3 with samples from OR patients (OR rate: 65%, P¼ 0.031),
whereas cluster 2 included an intermediate proportion of OR
samples (52%), suggesting an association between expression of
CXCL9, CXCL10, CXCL11 and CCL5 and immune responsiveness.
CXCL9, CXCL10, CXCL11 and CCL5 are the classical interferon
inducible chemokines and are coordinately regulated by STAT1
signalling (Chandrasekar et al, 2013; Rauch et al, 2013). No
correlation with CR or OR was observed when samples were
clustered according to the other markers (i.e., CCL3, CCL4,
CXCR3, and CCR5, Supplementary Figure S4).
DISCUSSION
Activated cytotoxic and helper-1 T cells express CXCR3 and CCR5
on cell surface (Franciszkiewicz et al, 2012). The intratumoral
overexpression of CXCR3 and/or CCR5 ligand genes in primary
Variable
OR Rate
OR vs NR
n = 142
Odds ratio
CCR5-Δ32 vs WT (DNA) 24% (6/25) vs 16%(19/116) 1.61 
CXCR3/CCR5 low vs high
(PPM) 
36% (17/47) vs 8%
(8/95) 6.16 
CCR5 low vs high (mRNA) 21% (15/71) vs 14%(10/71) 1.63
CXCR3 low vs high (mRNA) 25% (18/71) vs 10%(7/71) 3.11
CXCR3/CCR5 low vs high
(mRNA)  
32% (13/41) vs 12%
(12/101) 3.44
CCR5 low vs high (mRNA) 48% (34/71) vs 52%(37/71) 0.84
CCR5-Δ32 vs WT  (DNA) 68% (17/25) vs 46%(53/116) 2.53
CXCR3 low vs high  (mRNA) 54% (38/71) vs 47%(33/71) 1.33
CXCR3/CCR5 low vs high
(mRNA) 
59% (24/41) vs 47%
(47/101) 1.62
CXCR3/CCR5 low vs high
(PPM) 
64% (30/47) vs 43%
(41/95) 
2.32
DNA
RNA
RNA
RNA
PPM
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CR rate
CR vs non-CR
n = 142
Odds ratio
RNA
RNA
RNA
PPM
DNA
Objective response (OR vs NR)
CCR5 low vs high (PPM) 22% (19/85) vs 11%(6/57) 2.45
PPM
CCR5 low  vs high (PPM) 54% (46/85) vs 44%(25/57) 1.51 PPM
0 1 2 3 4 5 6 7
0 1 2 3 4 5 6 7
Complete response (CR vs non-CR)
Figure 1. Effect of CXCR3/CCR5 expression status of tumor-infiltrating lymphocytes (TILs) on complete response (A) and objective response (B).
Odds ratios are represented. CCR5-D32 (DNA): presence of D32 polymorphism; CCR5-D32 low (PPM): CCR5 low according to the PPM (CCR5
below the median value according to the gene expression data or presence of CCR5-D32 polymorphism); CCR5 low (mRNA): CCR5 below the
median value according to the gene expression data; CXCR3 low (RNA): CXCR3 below the median value according to the gene expression data;
CXCR3/CCR5 low (mRNA): CXCR3 and CCR5 below the median value according to the gene expression data; CXCR3/CCR5 low (PPM): CXCR3
and CCR5 below the median value according to the gene expression data or CXCR3 low and CCR5 high in presence of CCR5-D32 polymorphism.
P-values are from w2-test. Abbreviations: CI¼ confidence interval; CR¼ complete response; non-CR¼PRþNR; OR¼objective response (CRþPR);
PPM¼protein prediction model; PR¼partial response; WT¼wild-type.
CCR5 high transcript  expression CCR5 high protein expressio
CCR5 high transcript expression CCR5 low protein expressio
Δ32 Polymorphism 
Wild-type
A
B
Figure 2. Protein prediction model. In wild-type subjects (A) we
assume that high levels of CCR5 transcript are associated with high
expression of CCR5 on cell surface. However, because D32
polymorphism encodes a protein not expressed on the cell surface (B),
CCR5-D32 carriers were expected to have a low receptor expression
(decreased in heterozygous individuals and absent in homozygous
individuals) despite the high transcript expression.
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tumours has been correlated with high density of T cells and
reduced risk of relapse or death in the lung (CCL5; Moran et al,
2002), melanoma (CCL5, CXCL9, and CXCL10), ovarian, (CXCL9
and CCL5; Zhang et al, 2003; Leffers et al, 2010) colorectal (CCL5,
CXCL9, and CXCL10;Mlecnik et al, 2010; Tosolini et al, 2011), and
breast cancer (CCL5, CXCL9, and CXCL10; Ascierto et al, 2012;
Curtis et al, 2012). Consistently, Messina et al (2012) recently
reported a prolonged survival in metastatic melanoma patients
bearing tumours overexpressing CCL3, CCL4, CCL5, CXCL9,
CXCL10, and CXCL11 (Messina et al, 2012). In addition, these
chemokine genes have been associated with a higher likelihood to
respond to ipilimumab (CCL4, CCL5, CXCL9, CXCL10, and
CXCL11; Ji et al, 2012) and MAGE-A3 vaccination (CXCL9, CXCL10
and CCL5; Ulloa-Montoya et al, 2013) (Wang et al, 2013a).
Testing pretreatment biopsies from 113 melanoma patients
undergoing adoptive therapy, we observed that the coordinated
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activation of the classical interferon inducible chemokine CXCL9,
CXCL10, CXCL11 and CCL5 (Rauch et al, 2013) progressively
increases the probability of response to adoptive therapy. CXCL9,
CXCL10 and CCL5 represent the chemokines most frequently
associated with both favourable prognostic and predictive role
(Galon et al, 2013). We proposed that these chemokines identify a
specific cancer immune phenotype (‘Th1, interferon-driven
phenotype’) associated with better prognosis and responsiveness
to immune manipulations (Ascierto et al, 2011; Spivey et al, 2012;
Galon et al, 2013; Murtas et al, 2013).
We hypothesised that adoptively transferred TILs should be
most likely to be effective when expressing high levels of the
corresponding chemokine receptors. Ugurel et al (2008) reported
that metastatic melanoma patients who carried one or two
CCR5-D32 alleles suffer worse survival following immunotherapy
or immunochemotherapy. The results from the 142 TILs were in
apparent contradiction with this hypothesis. The CXCR3/CCR5
expression status was opposite than predicted. CCR5-D32 poly-
morphism, and CCR5 and CXCR3 transcript underexpression in
TILs were associated with downregulation of the corresponding
Figure 3. Correlation between CXCR3/CCR5 transcript and protein expression in tumour-infiltrating lymphocytes (TILs). (A) Scatter plot
representing the Spearman correlations between CXCR3 transcript (Log2 intensity, x axis) and protein expression (Fsp, y axis). (B) Overlaid
histograms representing three representative CR samples with low level of CXCR3 transcript and receptor expression, and three NR samples with
high level of CXCR3 transcript and receptor expression (according to the median value). Each sample is stained with CXCR3-PE (light blue graph)
or with the corresponding IC (red graph). (C) Box plots showing the comparisons between samples with different CCR5 expression values (low and
high according to the median value based on gene expression) and CCR5-D32 status (x axes): (D) Overlaid histograms exhibiting three
representative CR samples with low level of CCR5 transcript and receptor expression and three NR samples with high level of CCR5 receptor
expression (according to the median value). CR panel includes two CCR5 wild-type samples and one CCR5-D32 heterozygous sample. NR panel
includes three CCR5 wild-type samples. Each sample is stained with CCR5-FITC (light blue graph) or with the corresponding IC (red graph).
(E, F) Scatter plots representing the Spearman correlations between CCR5 transcript (Log2 intensity, x axis) and protein expression (Fsp, y axis)
within all the samples (E) or within the CCR5-D32 heterozygous samples (F). Box plots: the top and the bottom edge of the tinted boxes show the
values of the upper and lower quartiles, respectively. The top and the end of the whiskers represent the maximum and the minimum values
excluding the outliers (which are plotted as individual dots). The horizontal lines indicate the median value. Specific fluorescent signal (Fsp) was
calculated on live cells (7AAD negative) by normalising to the respective isotype control. Abbreviations: D32 Het mRNA low¼CCR5-D32
heterozygous and CCR5 mRNA low; D32 Het mRNA high¼CCR5-D32 heterozygous and CCR5 mRNA high; D32 Hom¼CCR5-D32 homozygous;
CR¼ complete response; PR¼partial response; WT mRNA low¼CCR5 wild-type and CCR5 mRNA low; WT mRNA high¼CCR5 wild-type and
CCR5 mRNA low; y axis represents CCR5-specific fluorescence signal (Fsp). P-values are from the Spearman rank correlation coefficient (r) test.
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Figure 4. Flow cytometry analysis of CXCR3 and CCR5 receptor expression by tumour-infiltrating lymphocytes (TILs). (A) Scatter plot of CXCR3
and CCR5 protein expression on cells surface. x axis: CCR5-specific fluorescent signal (Fsp); y axis: CXCR3-specific fluorescent signal (Fsp). Vertical
and horizontal dotted lines represent the median values of the x and y axes, respectively. CR samples are represented with red dots, PR samples
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median value) are represented. CR panel includes two CCR5 wild-type samples and one CCR5-D32 heterozygous sample. NR panel includes three
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(CRþPR); PR=partial response.
BRITISH JOURNAL OF CANCER CXCR3/CCR5 pathways in adoptive therapy
2420 www.bjcancer.com |DOI:10.1038/bjc.2013.557
receptors and higher likelihood (OR rate) and degree (CR rate) of
response. The association with achievement of a CR is intriguing
and particularly relevant as CR patients treated with adoptive
therapy usually experience a extremely durable remission (up to
100% of overall survival at 3 years (Rosenberg et al, 2011)). The
strength of the association with response progressively increased as
CCR5 and CXCR3 expression data were combined and were
integrated with CCR5 sequencing data, as indicated by the log
likelihood test for models.
These counterintuitive and surprising results could be explained
by the dynamics of TIL migration to the tumour in relation to
concomitant IL-2 administration. Localisation of TILs to the
tumour site is necessary for their antitumour activity (Pockaj et al,
1994). However, soon (2 h) after high-dose IL-2 administration, the
infused TILs rapidly disappear from the circulation. They do not
localise to tumour tissue and rather migrate to normal liver, lung,
and spleen (Fisher et al, 1989). Migration to the tumour begins 24
or 48 h after IL-2 administration and increases over time during
the following days (Fisher et al, 1989). However, concentrations of
CCR5 and CXCR3 ligands (e.g., CCL3, CCL4, CXCL9, CXCL10
and CXCL11) increase immediately after IL-2 administration
(Panelli et al, 2004b). Our previous genomic and proteomic studies
suggest that IL-2 seems to exert its effect on the tumour site
indirectly by inducing monocyte activation, followed by a delayed,
dose-dependent release of chemoattractants such as CXCR3 and
CCR5 ligands that recruit TILs only in the later stages of treatment
(Panelli et al, 2002; Wang et al, 2002; Panelli et al, 2004b; Weiss
et al, 2011). In fact, administration of IL-2 is followed by a rapid
clearance of peripheral mononuclear cells, without any evidence of
their migration to tumour metastases at early time points (Panelli
et al, 2002), consistently with results from adoptive therapy studies
(Pockaj et al, 1994). Several richly perfused organs including the
lung and liver, populated with IL-2-receptor carrying cells, are
probably the primary target of systemic IL-2 administration, and it
is there where the inflammatory cytokine storm is probably
initiated leading, among others, to the production of massive
quantities of CXCR3 and/or CCR5 ligands. A significant associa-
tion was reported with increased persistence of TILs in the
circulation 1 month following treatment and likelihood of clinical
response (Dudley et al, 2002; Rosenberg et al, 2011). It is tempting
to hypothesise that a low expression of chemokine receptors by
TILs in the acute phases of treatment might prevent their
sequestration by extratumoral tissues and paradoxically allow their
subsequent localisation to the tumour when the cytokine storm has
subsided and the tumour remains the only tissue maintaining
expression of chemokines. This hypothesis would be consistent
with the favourable predictive weight that higher expression of
CXCL9, CXCL10, CXCL11, and CCL5 in steady state conditions
confers. The enhancement of the expression of these chemokines
in tumour/tumour microenvironment could identify novel
strategies for the improvement of current immunotherapies
(Muthuswamy et al, 2012; Pescatori et al, 2013).
These ligands could modulate the tumour microenvironment in
other ways, independently of the recruitment of T cells. CCR5
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Figure 5. CXCR3/CCR5 ligands gene expression in pretreatment biopsies. (A) Hierarchical clustering of gene–gene correlation from 113
pretreatment tumours. The Spearman rank correlation coefficient (r) was calculated between combination of CXCR3, CCR5, CXCR3 ligands
(CXCL9, CXCL10, and CXCL11) and CCR5 ligands (CCL3, CCL4, and CCL5). CXCL9, CXCL10, CXCL11 and CCL5 clustered together and were
selected for hierarchical clustering analysis based on the mean-centered gene expression values (B). Patients with clinical complete responses (CR)
are shown in red, patients with partial remission (PR) are shown in green and non-responders (NR) are shown in blue. Abbreviations: non-
CR¼PRþNR; OR¼objective response (CRþPR). P-values are from the w2-test.
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blockade, for example, has been demonstrated to enhance
proliferation of xenografts from breast cancer cells bearing WT
p53, and the presence of D32 polymorphism has been associated
with higher risk of relapse in breast cancer patients with p53 WT
tumours (Manes et al, 2003). Thus, the aforementioned observa-
tion of Ugurel et al (2008) only apparently clashes with our
findings. As response rate was not assessed in that study, the D32
polymorphism mutation may have enhanced tumour growth
through a direct effect on tumour biology (Manes et al, 2003),
resulting in the observed poor survival in these patients (Ugurel
et al, 2008). As in our study the presence of CCR5-D32 mutation
was not associated with worse response (and rather, when
considered as single parameter, it was marginally associated with
better OR, P¼ 0.043), it is likely that the direct modulation of
CCR5 in cancer tumour cells has a little (if any) impact on the
clinical outcome of patients undergoing adoptive therapy.
However, it is possible that aside from the adoptive transfer
model, when activated CXCR3þ /CCR5þ TILs are infused
in combination with high-dose IL-2, during other treatments
(e.g., combination of immunochemotherapy (Ugurel et al, 2008)),
the proportional induction of the CXCR3 and CCR5 ligands
following treatment is not as unbalanced as it is in our study.
Although we stress that our findings must be prospectively
validated, the significance of our observation is supported by the
fact that it does not come from a merely retrospective
investigation. Retrospective investigations performed on archived
specimens are often conducted independent of a specified protocol
and are unfocused, with numerous patient subsets and end points
(Simon et al, 2009). Our prospective-retrospective (Simon et al,
2009) investigation was rather designed to study specimens
collected during prospective trials and specifically stored to
preserve DNAs, mRNAs and proteins in order to perform the
dedicated assays.
Animal models can provide important mechanistic insights into
human diseases. Studies in mouse models employing adoptively
transferred lymphocytes have emphasised a key role of the
upregulation of CCR5 in TILs in mediating tumour rejection
(Gonzalez-Martin et al, 2012). Our present study, however, fails to
demonstrate that the downregulation of CCR5 in TIL is a
detrimental factor in this setting in humans.
However, in view of the intrinsic limitations of the investigation
(e.g., the possible data overfitting because of the use of regression
models), our results should be considered exploratory and need to
be validated by integrated quantitative PCR, sequencing, and flow
cytometric analyses in an independent cohort of patients.
Considering the complexity of tumour–host interactions, we
believe that only a prospective clinical translation study employing
serial biopsies (i.e., pre- and post treatment) in different tissues and
specifically designed to asses T-cell tumour trafficking in humans can
conclusively confirm the hypotheses generated by our present report.
In conclusion, our study identified candidate biomarkers of
immune responsiveness in this setting by applying a combinatorial
multifactorial approach. In fact, none of the individual parameters
assessed had predictive value alone, but the coordinated analysis of
the two molecules corrected for the predicted function according to
the genetic polymorphism yielded strong predictive value. This
point proposes a paradigm shift for the identification of clinically
relevant biomarkers in complex biological problems. The optimi-
sation of this approach in genomic-scale models represents a future
challenge (Wang et al, 2013b).
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